Cullen Frost Bankers Inc. Sells 445 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Cullen Frost Bankers Inc. cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,423 shares of the biopharmaceutical company’s stock after selling 445 shares during the period. Cullen Frost Bankers Inc.’s holdings in Regeneron Pharmaceuticals were worth $3,372,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in REGN. Brighton Jones LLC grew its holdings in shares of Regeneron Pharmaceuticals by 261.8% in the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after purchasing an additional 686 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Regeneron Pharmaceuticals by 41.8% in the first quarter. GAMMA Investing LLC now owns 1,286 shares of the biopharmaceutical company’s stock worth $816,000 after purchasing an additional 379 shares during the last quarter. Oppenheimer Asset Management Inc. bought a new position in shares of Regeneron Pharmaceuticals in the first quarter worth about $1,246,000. Asset Management One Co. Ltd. grew its holdings in shares of Regeneron Pharmaceuticals by 3.9% in the first quarter. Asset Management One Co. Ltd. now owns 62,338 shares of the biopharmaceutical company’s stock worth $39,537,000 after purchasing an additional 2,358 shares during the last quarter. Finally, Legacy Advisors LLC grew its holdings in shares of Regeneron Pharmaceuticals by 20.2% in the first quarter. Legacy Advisors LLC now owns 435 shares of the biopharmaceutical company’s stock worth $276,000 after purchasing an additional 73 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $584.74 on Thursday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $959.60. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $61.98 billion, a PE ratio of 14.74, a P/E/G ratio of 1.81 and a beta of 0.31. The firm has a 50 day moving average of $576.17 and a two-hundred day moving average of $562.42.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company had revenue of $3.68 billion during the quarter, compared to analyst estimates of $3.30 billion. During the same period last year, the firm posted $11.56 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 3.6% compared to the same quarter last year. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.87%.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on REGN shares. Citigroup increased their target price on shares of Regeneron Pharmaceuticals from $650.00 to $660.00 and gave the stock a “buy” rating in a report on Monday, October 13th. Guggenheim increased their target price on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a “buy” rating in a report on Friday, August 1st. UBS Group reiterated a “neutral” rating on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Weiss Ratings reiterated a “hold (c-)” rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 8th. Finally, Wells Fargo & Company cut shares of Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $580.00 target price on the stock. in a report on Friday, August 1st. Three analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $817.88.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.